Wave II clinical study will evaluate THRV-1268, Thryv's oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2. Wave II is informed by the successful Wave I clinical study with LQT-1213 and ...

The MarketWatch News Department was not involved in the creation of this content. -- Wave II clinical study will evaluate THRV-1268, Thryv's oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2 ...

With nearly two decades of retail and project management experience, Brett Day can simplify traditional and Agile project management philosophies and methodologies and explain the features of project ...

Rudeness at work is rampant, and it’s on the rise. Over the past 14 years we’ve polled thousands of workers about how they’re treated on the job, and 98% have reported experiencing uncivil behavior.

Imagine you’re in a busy café, enjoying your latte, and you spot a woman across the room scrolling through her phone. You might wonder what small gesture could turn a quick glance into a real ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...